A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients
Bandrés E, Malumbres R, Cubedo E, Honorato B, Zarate R, Labarga A, Gabisu U, Sola JJ, García-Foncillas J.
Laboratory of Pharmacogenomics, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain
Magazine: Oncology Reports
Date: May 1, 2007Medical Oncology Digestive Tract Tumours Area Clinical Genetics Unit [SP]
The benefit of postoperative adjuvant chemotherapy in patients with Dukes' B colorectal cancer is still uncertain and its routine use is not recommended. The five-year relapse rate is approximately 25-40% and the identification of patients at high risk of recurrence would represent an important strategy for the use of adjuvant chemotherapy.
We retrospectively analyzed gene expression profiles in frozen tumor specimens from patients with Dukes' B colorectal cancer by using high density oligonucleotide microarrays.
Our results show a subset of 48 genes differentially expressed with an associated probability <0.001 in the t-test. Another statistical procedure based on the Fisher criterion resulted in 11 genes able to separate both groups. We selected the 8 genes present in both subsets. The differential expression of five genes (CHD2, RPS5, ZNF148, BRI3 and MGC23401) in colon cancer progression was confirmed by real-time PCR in an independent set of patients of Dukes' B and C stages.
CITATION Oncol Rep. 2007 May;17(5):1089-94
tal vezLE INTERESE
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.